Setting

Europe Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity

Published: 30 Dec 2021 | Report Code: 10248307 | Pages: 110

Europe monoclonal antibodies market was valued at $40.8 billion in 2020 and will grow by 11.0% annually over 2020-2030 owing to the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies. Highlighted with 34 tables and 52 figures, this 110-page report “Europe Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country. Based on Source, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Human • Humanized • Chimeric • Murine Based on Category, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Branded mAbs • Biosimilar mAbs Based on Production Type, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • In Vitro Production • In Vivo Production Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Cancer o Breast Cancer o Colorectal Cancer o Lung Cancer o Ovarian Cancer o Other Cancer Types • Autoimmune Diseases • Inflammatory Diseases • Infectious Diseases • Other Applications By End User, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Hospitals • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories AbbVie, Inc. Amgen Inc. AstraZeneca plc Bayer AG Bristol-Myers Squibb Company Eli Lilly F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Johnson & Johnson Merck & Co., Inc. Mylan N.V Norvatis AG Pfizer Sanofi S.A. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	20
2.1.2 Impact of COVID-19 on the Market	23
2.2 Major Growth Drivers	25
2.3 Market Restraints and Challenges	30
2.4 Emerging Opportunities and Market Trends	33
2.5 Porter’s Fiver Forces Analysis	37
3 Segmentation of Europe Market by Source	41
3.1 Market Overview by Source	41
3.2 Human	43
3.3 Humanized	44
3.4 Chimeric	45
3.5 Murine	46
4 Segmentation of Europe Market by Category	47
4.1 Market Overview by Category	47
4.2 Branded mAbs	49
4.3 Biosimilar mAbs	50
5 Segmentation of Europe Market by Production Type	51
5.1 Market Overview by Production Type	51
5.2 In Vitro Production	53
5.3 In Vivo Production	54
6 Segmentation of Europe Market by Application	55
6.1 Market Overview by Application	55
6.2 Cancer	57
6.2.1 Breast Cancer	59
6.2.2 Colorectal Cancer	60
6.2.3 Lung Cancer	61
6.2.4 Ovarian Cancer	62
6.2.5 Other Cancer Types	63
6.3 Autoimmune Diseases	64
6.4 Inflammatory Diseases	65
6.5 Infectious Diseases	66
6.6 Other Applications	67
7 Segmentation of Europe Market by End User	68
7.1 Market Overview by End User	68
7.2 Hospitals	70
7.3 Research Institutes	71
7.4 Other End Users	72
8 European Market 2019-2030 by Country	73
8.1 Overview of European Market	73
8.2 Germany	76
8.3 U.K.	78
8.4 France	80
8.5 Spain	82
8.6 Italy	84
8.7 Russia	86
8.8 Rest of European Market	88
9 Competitive Landscape	90
9.1 Overview of Key Vendors	90
9.2 New Product Launch, Partnership, Investment, and M&A	93
9.3 Company Profiles	94
Abbott Laboratories	94
AbbVie, Inc.	96
Amgen Inc.	97
AstraZeneca plc	98
Bayer AG	99
Bristol-Myers Squibb Company	100
Eli Lilly	101
F. Hoffmann-La Roche Ltd.	102
GlaxoSmithKline Plc	103
Johnson & Johnson	104
Merck & Co., Inc.	105
Mylan N.V	106
Norvatis AG	107
Pfizer	108
Sanofi S.A.	109
RELATED REPORTS	110
List Of Tables:


Table 1.  Snapshot of Europe Monoclonal Antibodies Market in Balanced Perspective, 2019-2030	17
Table 2. Growth Rate of World GDP, 2020-2022	21
Table 3. World Health Spending by Region, $ bn, 2013-2020	29
Table 4.  Main Product Trends and Market Opportunities in Europe Monoclonal Antibodies Market	33
Table 5. Europe Monoclonal Antibodies Market by Source, 2019-2030, $ bn	41
Table 6. Europe Monoclonal Antibodies Market by Category, 2019-2030, $ bn	47
Table 7. Europe Monoclonal Antibodies Market by Production Type, 2019-2030, $ bn	51
Table 8. Europe Monoclonal Antibodies Market by Application, 2019-2030, $ bn	55
Table 9. Europe Monoclonal Antibodies Market: Cancer Therapy by Type, 2019-2030, $ bn	58
Table 10. Europe Monoclonal Antibodies Market by End User, 2019-2030, $ bn	68
Table 11. Europe Monoclonal Antibodies Market by Country, 2019-2030, $ bn	75
Table 12. Germany Monoclonal Antibodies Market by Source, 2019-2030, $ bn	77
Table 13. Germany Monoclonal Antibodies Market by Application, 2019-2030, $ bn	77
Table 14. Germany Monoclonal Antibodies Market by End User, 2019-2030, $ bn	77
Table 15. U.K. Monoclonal Antibodies Market by Source, 2019-2030, $ bn	79
Table 16. U.K. Monoclonal Antibodies Market by Application, 2019-2030, $ bn	79
Table 17. U.K. Monoclonal Antibodies Market by End User, 2019-2030, $ bn	79
Table 18. France Monoclonal Antibodies Market by Source, 2019-2030, $ bn	81
Table 19. France Monoclonal Antibodies Market by Application, 2019-2030, $ bn	81
Table 20. France Monoclonal Antibodies Market by End User, 2019-2030, $ bn	81
Table 21. Spain Monoclonal Antibodies Market by Source, 2019-2030, $ bn	83
Table 22. Spain Monoclonal Antibodies Market by Application, 2019-2030, $ bn	83
Table 23. Spain Monoclonal Antibodies Market by End User, 2019-2030, $ bn	83
Table 24. Italy Monoclonal Antibodies Market by Source, 2019-2030, $ bn	85
Table 25. Italy Monoclonal Antibodies Market by Application, 2019-2030, $ bn	85
Table 26. Italy Monoclonal Antibodies Market by End User, 2019-2030, $ bn	85
Table 27. Russia Monoclonal Antibodies Market by Source, 2019-2030, $ bn	87
Table 28. Russia Monoclonal Antibodies Market by Application, 2019-2030, $ bn	87
Table 29. Russia Monoclonal Antibodies Market by End User, 2019-2030, $ bn	87
Table 30. Monoclonal Antibodies Market in Rest of Europe by Country, 2019-2030, $ bn	89
Table 31. Abbott Laboratories: Company Snapshot	94
Table 32. Abbott Laboratories: Business Segmentation	94
Table 33. Abbott Laboratories: Product Portfolio	95
Table 34. Abbott Laboratories: Revenue, 2018-2020, $ bn	95
List of Figures:


Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	16
Figure 4. Europe Monoclonal Antibodies Market, 2019-2030, $ bn	19
Figure 5. Impact of COVID-19 on Business	23
Figure 6. Primary Drivers and Impact Factors of Europe Monoclonal Antibodies Market	25
Figure 7.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	28
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060	28
Figure 9. Primary Restraints and Impact Factors of Europe Monoclonal Antibodies Market	30
Figure 10. Investment Opportunity Analysis	34
Figure 11. Porter’s Fiver Forces Analysis of Europe Monoclonal Antibodies Market	37
Figure 12. Breakdown of Europe Monoclonal Antibodies Market by Source, 2019-2030, % of Revenue	42
Figure 13. Europe Addressable Market Cap in 2021-2030 by Source, Value ($ bn) and Share (%)	42
Figure 14. Europe Monoclonal Antibodies Market by Source: Human, 2019-2030, $ bn	43
Figure 15. Europe Monoclonal Antibodies Market by Source: Humanized, 2019-2030, $ bn	44
Figure 16. Europe Monoclonal Antibodies Market by Source: Chimeric, 2019-2030, $ bn	45
Figure 17. Europe Monoclonal Antibodies Market by Source: Murine, 2019-2030, $ bn	46
Figure 18. Breakdown of Europe Monoclonal Antibodies Market by Category, 2019-2030, % of Sales Revenue	48
Figure 19. Europe Addressable Market Cap in 2021-2030 by Category, Value ($ bn) and Share (%)	48
Figure 20. Europe Monoclonal Antibodies Market by Category: Branded mAbs, 2019-2030, $ bn	49
Figure 21. Europe Monoclonal Antibodies Market by Category: Biosimilar mAbs, 2019-2030, $ bn	50
Figure 22. Breakdown of Europe Monoclonal Antibodies Market by Production Type, 2019-2030, % of Sales Revenue	52
Figure 23. Europe Addressable Market Cap in 2021-2030 by Production Type, Value ($ bn) and Share (%)	52
Figure 24. Europe Monoclonal Antibodies Market by Production Type: In Vitro Production, 2019-2030, $ bn	53
Figure 25. Europe Monoclonal Antibodies Market by Production Type: In Vivo Production, 2019-2030, $ bn	54
Figure 26. Breakdown of Europe Monoclonal Antibodies Market by Application, 2019-2030, % of Revenue	56
Figure 27. Europe Addressable Market Cap in 2021-2030 by Application, Value ($ bn) and Share (%)	56
Figure 28. Europe Monoclonal Antibodies Market by Application: Cancer, 2019-2030, $ bn	57
Figure 29. Europe Monoclonal Antibodies Market by Cancer Type: Breast Cancer, 2019-2030, $ bn	59
Figure 30. Europe Monoclonal Antibodies Market by Cancer Type: Colorectal Cancer, 2019-2030, $ bn	60
Figure 31. Europe Monoclonal Antibodies Market by Cancer Type: Lung Cancer, 2019-2030, $ bn	61
Figure 32. Europe Monoclonal Antibodies Market by Cancer Type: Ovarian Cancer, 2019-2030, $ bn	62
Figure 33. Europe Monoclonal Antibodies Market by Cancer Type: Other Cancer Types, 2019-2030, $ bn	63
Figure 34. Europe Monoclonal Antibodies Market by Application: Autoimmune Diseases, 2019-2030, $ bn	64
Figure 35. Europe Monoclonal Antibodies Market by Application: Inflammatory Diseases, 2019-2030, $ bn	65
Figure 36. Europe Monoclonal Antibodies Market by Application: Infectious Diseases, 2019-2030, $ bn	66
Figure 37. Europe Monoclonal Antibodies Market by Application: Other Applications, 2019-2030, $ bn	67
Figure 38. Breakdown of Europe Monoclonal Antibodies Market by End User, 2019-2030, % of Revenue	69
Figure 39. Europe Addressable Market Cap in 2021-2030 by End User, Value ($ bn) and Share (%)	69
Figure 40. Europe Monoclonal Antibodies Market by End User: Hospitals, 2019-2030, $ bn	70
Figure 41. Europe Monoclonal Antibodies Market by End User: Research Institutes, 2019-2030, $ bn	71
Figure 42. Europe Monoclonal Antibodies Market by End User: Other End Users, 2019-2030, $ bn	72
Figure 43. Breakdown of European Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue	74
Figure 44. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%)	75
Figure 45.  Monoclonal Antibodies Market in Germany, 2019-2030, $ bn	76
Figure 46.  Monoclonal Antibodies Market in U.K., 2019-2030, $ bn	78
Figure 47.  Monoclonal Antibodies Market in France, 2019-2030, $ bn	80
Figure 48.  Monoclonal Antibodies Market in Spain, 2019-2030, $ bn	82
Figure 49.  Monoclonal Antibodies Market in Italy, 2019-2030, $ bn	84
Figure 50.  Monoclonal Antibodies Market in Russia, 2019-2030, $ bn	86
Figure 51.  Monoclonal Antibodies Market in Rest of Europe, 2019-2030, $ bn	88
Figure 52. Growth Stage of Europe Monoclonal Antibodies Industry over the Forecast Period	90
Key Players (this may not be a complete list and extra companies can be added upon request): 
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)